Table 3.
Results of Subgroup Analyses Under the WTP Set as 1.5 Times and 3 Times Chinese GDP per Capita
| Subgroup | HR for OS | ICER, US$/QALY | Cost-Effectiveness Probability (%) | |
|---|---|---|---|---|
| 3 Times GDP per Capita | 1.5 Times GDP per Capita | |||
| Age | ||||
| <65 years | 0.73 | 21,126.44 | 97.0% | 48.2% |
| ≥65 years | 0.62 | 16,988.55 | 99.9% | 80.2% |
| Sex | ||||
| Male | 0.72 | 20,662.67 | 99.8% | 51.5% |
| Female | 0.46 | 13,368.01 | 100% | 98.4% |
| Smoking status | ||||
| Current or former smoker | 0.65 | 17,935.24 | 99.5% | 74.3% |
| Never | 0.77 | 23,222.93 | 94.2% | 37.3% |
| Investigator-chosen chemotherapy* | ||||
| Platinum with fluoropyrimidine | 0.66 | 18,276.94 | 99.4% | 70.8% |
| Platinum with paclitaxel | 0.69 | 19,391.89 | 98.8% | 61.9% |
| ECOG | ||||
| 0 | 0.72 | 20,662.67 | 99.8% | 51.5% |
| 1 | 0.66 | 18,276.94 | 99.4% | 70.8% |
| Geographical region analysis 1 | ||||
| Asia | 0.67 | 18,633.01 | 99.3% | 70.0% |
| Other regions | 0.66 | 18,276.94 | 99.4% | 70.8% |
| Geographical region analysis 2 | ||||
| Asia (excluding Japan) | 0.70 | 19,796.68 | 98.6% | 60.1% |
| Japan | 0.49 | 13,906.40 | 100% | 97.4% |
| Other regions | 0.66 | 18,276.94 | 99.4% | 70.8% |
| Race | ||||
| Asian and other races† | 0.69 | 19,391.89 | 98.8% | 61.9% |
| White | 0.61 | 16,696.79 | 100% | 83.5% |
| Disease status at study entry | ||||
| Metastatic | 0.72 | 20,662.67 | 98.0% | 51.5% |
| Locally advanced | 0.44 | 13,036.34 | 100% | 99.1% |
| Previous definitive therapy* | ||||
| Yes | 0.67 | 18,633.01 | 99.3% | 70.0% |
| No | 0.68 | 19,004.34 | 99.2% | 63.5% |
Notes: *Per case report form. †Other races include American Indian, Alaska Native, not reported, and unknown.
Abbreviations: HR, hazard ratio; ECOG, Eastern Cooperative Oncology Group; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.